Cecolin 9

Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial

DATE  June 30, 2026
Title Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial
Journal The Lancet Infectious Diseases, 2026;
Authors Hong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, Shang-Ying Hu, Li Zhang, Kong-Xin Zhu, Kai Chu, Ying Hong, Shu-Fang Chang, Qin-Jing Pan, Xun Zhang, Jin-Bo Xu, Jie Tang, Dong-Ya Yuan, Hui Jiang, Chao Du, Guang Sun, Guo-Hua Zhong, Qi Chen, Li-Hui Wei, You-Lin Qiao, Shao-Wei Li, Ying-Ying Su, Qiu-Fen Zhang, Shou-Jie Huang, Fang-Hui Zhao, Wei-Jin Huang, Ting Wu, Jun Zhang, Ning-Shao Xia
DOI https://doi.org/10.1016/S1473-3099(26)00221-5

Immunogenicity and safety of an Escherichia coli-produced 9-valent HPV vaccine in adolescents aged 9 to 17 compared with young women

DATE April  15, 2026
Title Immunogenicity and safety of an Escherichia coli-produced 9-valent HPV vaccine in adolescents aged 9 to 17 compared with young women
Journal Science Bulletin;
Authors Yulin Jing, Xiaowen Hu, Li Zhang, Jiangyahui Wang, Fei Yang, Rong Wang, Ying Jiang, Lingling Nie, Zhongqiang Jin, Xuecheng Liu, Sihai Li, Chao Du, Pengjuan Wang, Kun Li, Qi Chen, Shoujie Huang, Zhaofeng Bi, Qiufen Zhang, Weijin Huang, Yingying Su, Ting Wu, Jun Zhang, Ningshao Xia
DOI https://doi.org/10.1016/j.scib.2026.02.035

Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18–26 years: three-year follow-up data from a randomised clinical trial

DATE August 26, 2025
Title Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18–26 years: three-year follow-up data from a randomised clinical trial
Journal The Lancet Regional Health – Western Pacific, 2025; 62
Authors Guo-Hua Zhong, Zhao-Feng Bi, Kai Chu, Li Zhang, Lu Chen, Kong-Xin Zhu, Jia-Li Quan, Chu Nie, Qi Chen, Ling-Xian Qiu, Jin-Bo Xu, Jia-Xue Li, Ming-Lei Zhang, Sheng Liu, Ling-Ling Nie, Kun Li, Ying-Ying Su, Shou-Jie Huang, Qiu-Fen Zhang, Wei-Jin Huang, Hong-Xing Pan, Ting Wu, Jun Zhang, and Ning-Shao Xia
DOI https://doi.org/10.1016/j.lanwpc.2025.101671

Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial

DATE October 30, 2023
Title Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial
Journal Science Bulletin, Volume 68, Issue 20
Authors Yue-Mei Hu, Zhao-Feng Bi, Ya Zheng, Li Zhang, Feng-Zhu Zheng, Kai Chu, Ya-Fei Li, Qi Chen, Jia-Li Quan, Xiao-Wen Hu, Xing-Cheng Huang, Kong-Xin Zhu, Ya-Hui Wang-Jiang, Han-Min Jiang, Xia Zang, Dong-Lin Liu, Chang-Lin Yang, Hong-Xing Pan, Qiu-Fen Zhang, Ying-Ying Su, Shou-Jie Huang, Guang Sun, Wei-Jin Huang, Yue Huang, Ting Wu, Jun Zhang, Ning-Shao Xia
DOI https://doi.org/10.1016/j.scib.2023.09.020

Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial

DATE July 17, 2023
Title Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial
Journal The Lancet Infectious Diseases, 2023; 23, 1313-1322
Authors Feng-Cai Zhu, Guo-Hua Zhong, Wei-Jin Huang, Kai Chu, Li Zhang, Zhao-Feng Bi, Kong-Xin Zhu, Qi Chen, Ting-Quan Zheng, Ming-Lei Zhang, Sheng Liu, Jin-Bo Xu, Hong-Xing Pan, Guang Sun, Feng-Zhu Zheng, Qiu-Fen Zhang, Xiu-Mei Yi, Si-Jie Zhuang, Shou-Jie Huang, Hui-Rong Pan, Ying-Ying Su, Ting Wu, Jun Zhang, Ning-Shao Xia
DOI https://doi.org/10.1016/S1473-3099(23)00275-X

Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial

DATE March 12, 2023
Title Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial
Journal The Lancet Regional Health – Western Pacific, 2023; 34
Authors Kai Chu, Zhao-Feng Bi, Wei-Jin Huang, Ya-Fei Li, Li Zhang, Chang-Lin Yang, Han-Min Jiang, Xia Zang, Qi Chen, Dong-Lin Liu, Hong-Xing Pan, Yue Huang, Feng-Zhu Zheng, Qiu-Fen Zhang, Guang Sun, Ying-Ying Su, Shou-Jie Huang, Hui-Rong Pan, Ting Wu, Yue-Mei Hu, Jun Zhang, Feng-Cai Zhu, and Ning-Shao Xia
DOI https://doi.org/10.1016/j.lanwpc.2023.100731

Cecolin

Immunogenicity and safety of co-administered Escherichia coli-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine

DATE May 29, 2026
Title Immunogenicity and safety of co-administered Escherichia coli-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine
Journal Frontiers in Immunology, 2026; 17:1837539
Authors Rui Yan, Mengting Cen, Yang Zhou, Liyang Ma, Xiaofei Zhou, Hanqing He, Xiaohua Qi, Xuewen Tang, Hui Liang, Yaping Chen, Jiaxing Qi, Shigui Yang
DOI https://doi.org/10.3389/fimmu.2026.1837539

Memory Cell and Antibody Responses Following a Single Versus Two Doses of Escherichia coli-Produced Vaccine Against Human Papillomavirus Types 16 and 18: A Real-World Study in Chinese Girls

DATE May 20, 2026
Title Memory Cell and Antibody Responses Following a Single Versus Two Doses of Escherichia coli-Produced Vaccine Against Human Papillomavirus Types 16 and 18: A Real-World Study in Chinese Girls
Journal International Journal of Cancer, 2026; 0:1–13
Authors Tianmeng Wen, Li Dong, Jiayi Li, Yushu Feng, Lingling Nie, Zhongliang Li, Li Zhang, Shangying Hu, Weijin Huang, Fanghui Zhao, Partha Basu
DOI https://doi.org/10.1002/ijc.70553

Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years

DATE January 14, 2026
Title Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years
Journal Nature Communications, 2026; 17:1677
Authors Qi Chen, Jiali Quan, Kongxin Zhu, Linchen Lan, Jiaoxi Lu, Linfeng Zhu, Bin Zhang, Guohua Zhong, Zhaofeng Bi, Shoujie Huang, Yingying Su, Lihui Wei, Youlin Qiao, Jun Zhang, Ting Wu, Ningshao Xia
DOI https://doi.org/10.1038/s41467-026-68379-3

Immunopersistence of one or two doses of an Escherichia coli produced bivalent HPV vaccine

DATE December 1, 2025
Title Immunopersistence of one or two doses of an Escherichia coli produced bivalent HPV vaccine
Journal npj Vaccines, 2026; 11:16
Authors Mengjun Liao, Jiali Quan, Kongxin Zhu, Xiaowen Hu, Shudan Shen, Jianhua Xu, Chu Nie, Weizhuo Xu, Hexuan Jiang, Xianliang Wu, Yanqin Zhong, Yuhang Peng, Shihui Cai, Jie Chen, Chengzong Zhang, Bizhen Lin, Yingying Su, Shoujie Huang, Qi Chen, Ting Wu, Jun Zhang, Ningshao Xia
DOI https://doi.org/10.1038/s41541-025-01335-2

Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort

DATE August 21, 2025
Title Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort
Journal The Lancet Regional Health – Western Pacific, 2025; 61:101668
Authors Fanghui Zhao, Qi Chen, Chao Zhao, Lingling Nie, Shangying Hu, Jian Yin, Lingxian Qiu, Zhaofeng Bi, Jiali Quan, Yufei Li, Mingzhu Li, Xun Zhang, Qinjing Pan, Caihong Li, Lidong Ke, Xiaoli Liu, Fengxian Zheng, Cuihong Dai, Zhe Wang, Xuefeng Kuang, Xinhua Jia, Yingying Su, Shoujie Huang, Qiufen Zhang, Weijin Huang, Lihui Wei, Jun Zhang, Ting Wu, Youlin Qiao, Ningshao Xia
DOI https://doi.org/10.1016/j.lanwpc.2025.101668

Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9–14 years: A randomized and open-label clinical trial

DATE March 21, 2025
Title Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9–14 years: A randomized and open-label clinical trial
Journal Vaccine, 2025; 55:127015
Authors Fangqin Xie, Kaili Du, Junrong Li, Sumei Zhong, Chun Fan, Zhaofeng Bi, Qiufen Zhang, Jiandong Chen, Shanshan Ma, Dongjuan Zhang
DOI https://doi.org/10.1016/j.vaccine.2025.127015

Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial

DATE March 19, 2025
Title Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial
Journal The Lancet Infectious Diseases, 2025; 25:861–872
Authors Tsiri Agbenyega, Anne E Schuind, Samuel Adjei, Kalpana Antony, John J Aponte, Patrick B Y Buabeng, John D Clemens, Lokman Hossain, Troy J Kemp, Laina D Mercer, Ligia A Pinto, Firdausi Qadri, Kristen Sukraw, Niranjan Bhat, Khalequ Zaman
DOI https://doi.org/10.1016/S1473-3099(25)00031-3

Long-term protective efficacy of the Escherichia coli-produced HPV-16/18 bivalent human papillomavirus vaccine in women vaccinated at 18–45 years: A 9-year follow-up study

DATE January 10, 2025
Title Long-term protective efficacy of the Escherichia coli-produced HPV-16/18 bivalent human papillomavirus vaccine in women vaccinated at 18–45 years: A 9-year follow-up study
Journal Infectious Medicine, 2025; 4(1):100164
Authors Xinhua Jia, Shangying Hu, Xuefeng Kuang, Youlin Qiao
DOI https://doi.org/10.1016/j.imj.2025.100164

Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9–14 years of age: Interim analysis from a phase 3 clinical trial

DATE April 2, 2024
Title Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9–14 years of age: Interim analysis from a phase 3 clinical trial
Journal Vaccine, 2024; 42(9):2290–2298
Authors Khalequ Zaman, Anne E Schuind, Samuel Adjei, Kalpana Antony, John J Aponte, Patrick B Y Buabeng, Firdausi Qadri, Troy J Kemp, Lokman Hossain, Ligia A Pinto, Kristen Sukraw, Niranjan Bhat, Tsiri Agbenyega
DOI https://doi.org/10.1016/j.vaccine.2024.02.077

Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial

DATE March 15, 2023
Title Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial
Journal Emerging Microbes & Infections, 2023; 12: 2185456
Authors Guohua Zhong, Chunlan Zhuang, Xiaowen Hu, Qi Chen, Zhaofeng Bi, Xinhua Jia, Siying Peng, Yufei Li, Yue Huang, Qiufen Zhang, Ying Hong, Youlin Qiao, Yingying Su, Huirong Pan, Ting Wu, Lihui Wei, Shoujie Huang, Jun Zhang, and Ningshao Xia
DOI https://doi.org/10.1080/22221751.2023.2185456

Efficacy, safety, and immunogenicity of an Escherichia coli-produced human papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

DATE August 26, 2022
Title Efficacy, safety, and immunogenicity of an Escherichia coli-produced human papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
Journal The Lancet Infectious Diseases, 2022; 22:1756–1768
Authors Fang-Hui Zhao, Ting Wu, Yue-Mei Hu, Li-Hui Wei, Ming-Qiang Li, Wei-Jin Huang, Wen Chen, Shou-Jie Huang, Qin-Jing Pan, Xun Zhang, Ying Hong, Chao Zhao, Qing Li, Kai Chu, Yun-Fei Jiang, Ming-Zhu Li, Jie Tang, Cai-Hong Li, Dong-Ping Guo, Li-Dong Ke, Xin Wu, Xing-Mei Yao, Jian-Hui Nie, Bi-Zhen Lin, Yu-Qian Zhao, Meng Guo, Jun Zhao, Feng-Zhu Zheng, Xiao-Qian Xu, Ying-Ying Su, Qiu-Fen Zhang, Guang Sun, Feng-Cai Zhu, Shao-Wei Li, Yi-Min Li, Hui-Rong Pan, Jun Zhang, You-Lin Qiao, Ningshao Xia
DOI https://doi.org/10.1016/S1473-3099(22)00435-2

Comparison of HPV-neutralizing and IgG antibodies in unvaccinated female adolescents

DATE July 29, 2022
Title Comparison of HPV-neutralizing and IgG antibodies in unvaccinated female adolescents
Journal Future Microbiology, 2022; 17(15):1207–1215
Authors Xingmei Yao, Kai Chu, Jun Zhao, Yuemei Hu, Zhijie Lin, Bizhen Lin, Qi Chen, Yafei Li, Qiufen Zhang, Mujin Fang, Shoujie Huang, Yingbin Wang, Yingying Su, Ting Wu, Jun Zhang, Ningshao Xia
DOI https://doi.org/10.2217/fmb-2021-0221

Long-term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls

DATE April 13, 2022
Title Long-term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls
Journal Human Vaccines & Immunotherapeutics, 2022; 18(5)
Authors Xingmei Yao, Wengang He, Xianghong Wu, Jianxiang Gu, Jing Zhang, Bizhen Lin, Zhaofeng Bi, Yingying Su, Shoujie Huang, Yuemei Hu, Ting Wu, Jun Zhang, Ningshao Xia
DOI https://doi.org/10.1080/21645515.2022.2061248

Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study

DATE July 16, 2021
Title Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study
Journal The Lancet Regional Health – Western Pacific, 2021; 13:100196
Authors Xingmei Yao, Wen Chen, Chao Zhao, Lihui Wei, Yuemei Hu, Mingqiang Li, Zhijie Lin, Bizhen Lin, Xiaohui Liu, Ying Hong, Qing Li, Qinjing Pan, Xun Zhang, Mingzhu Li, Yuqian Zhao, Li Zhang, Huifang Xu, Fangfang Hu, Jun Zhao, Yue Huang, Wei Sheng, Ya Zheng, Shangying Hu, Yingying Su, Shoujie Huang, Huirong Pan, Fanghui Zhao, Youlin Qiao, Ting Wu, Jun Zhang, Ningshao Xia
DOI https://doi.org/10.1016/j.lanwpc.2021.100196

Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response

DATE March 1, 2021
Title Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response
Journal Emerging Microbes & Infections, 2021; 10(1):365–375
Authors Chun-Lan Zhuang, Zhi-Jie Lin, Zhao-Feng Bi, Ling-Xian Qiu, Fang-Fang Hu, Xiao-Hui Liu, Bi-Zhen Lin, Ying-Ying Su, Hui-Rong Pan, Tian-Ying Zhang, Shou-Jie Huang, Yue-Mei Hu, You-Lin Qiao, Feng-Cai Zhu, Ting Wu, Jun Zhang, Ningshao Xia
DOI https://doi.org/10.1080/22221751.2021.1891002

Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages

DATE July 24, 2020
Title Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages
Journal Vaccine, 2020; 38:6096–6102
Authors Qi Chen, Hui Zhao, Xingmei Yao, Zhijie Lin, Juan Li, Bizhen Lin, Rui Wang, Yue Huang, Yingying Su, Ting Wu, Changgui Li, Huirong Pan, Shoujie Huang, Jun Zhang, Ningshao Xia
DOI https://doi.org/10.1016/j.vaccine.2020.07.030

Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals

DATE June 16, 2020
Title Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals
Journal Human Vaccines & Immunotherapeutics, 2020
Authors Xiao-Juan Yu, Juan Li, Zhi-Jie Lin, Hui Zhao, Bi-Zhen Lin, You-Lin Qiao, Yue-Mei Hu, Li-Hui Wei, Rong-Cheng Li, Wei-Dan Huang, Ting Wu, Shou-Jie Huang, Chang-Gui Li, Hui-Rong Pan, Jun Zhang
DOI https://doi.org/10.1080/21645515.2020.1761202

Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18–45 years enrolled in a clinical trial

DATE January 3, 2020
Title Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18–45 years enrolled in a clinical trial
Journal Clinical Microbiology and Infection, 2020; 26:1069–1075
Authors Lihui Wei, Ying-Ying Su, Yuemei Hu, Rong-Cheng Li, Wen Chen, Qinjing Pan, Xun Zhang, Fang-Hui Zhao, Yu-Qian Zhao, Qing Li, Ying Hong, Chao Zhao, Ming-Qiang Li, Wen-Yu Liu, Cai-Hong Li, Dong-Ping Guo, Li-Dong Ke, Bi-Zhen Lin, Zhi-Jie Lin, Si Chen, Wei Sheng, Zi-Zheng Zheng, Si-Jie Zhuang, Feng-Cai Zhu, Hui-Rong Pan, Yi-Min Li, Shou-Jie Huang, Jun Zhang, You-Lin Qiao, Ting Wu, Ningshao Xia
DOI https://doi.org/10.1016/j.cmi.2019.12.010

Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial

DATE November 26, 2019
Title Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial
Journal Human Vaccines & Immunotherapeutics, 2020; 16(7):1636–1644
Authors Ying-Ying Su, Bi-Zhen Lin, Hui Zhao, Juan Li, Zhi-Jie Lin, You-Lin Qiao, Li-Hui Wei, Yue-Mei Hu, Rong-Cheng Li, Si-Jie Zhuang, Guang Sun, Zi-Zheng Zheng, Shou-Jie Huang, Ting Wu, Jun Zhang, Hui-Rong Pan, Chang-Gui Li
DOI https://doi.org/10.1080/21645515.2019.1691413

Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women

DATE June 21, 2019
Title Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women
Journal Science China Life Sciences, 2020; 63:582–591
Authors Yue-Mei Hu, Meng Guo, Chang-Gui Li, Kai Chu, Wen-Gang He, Jing Zhang, Jian-Xiang Gu, Juan Li, Hui Zhao, Xiang-Hong Wu, Bi-Zhen Lin, Zhi-Jie Lin, Xing-Mei Yao, Ya-Fei Li, Fei-Xue Wei, Yue Huang, Ying-Ying Su, Feng-Cai Zhu, Shou-Jie Huang, Hui-Rong Pan, Ting Wu, Jun Zhang, Ningshao Xia
DOI https://doi.org/10.1007/s11427-019-9547-7

Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial

DATE May 14, 2019
Title Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial
Journal Journal of the National Cancer Institute, 2020; 112(2):djz074
Authors You-Lin Qiao, Ting Wu, Rong-Cheng Li, Yue-Mei Hu, Li-Hui Wei, Chang-Gui Li, Wen Chen, Shou-Jie Huang, Fang-Hui Zhao, Ming-Qiang Li, Qin-Jing Pan, Xun Zhang, Qing Li, Ying Hong, Chao Zhao, Wen-Hua Zhang, Yan-Ping Li, Kai Chu, Mei Li, Yun-Fei Jiang, Juan Li, Hui Zhao, Zhi-Jie Lin, Xue-Lian Cui, Wen-Yu Liu, Cai-Hong Li, Dong-Ping Guo, Li-Dong Ke, Xin Wu, Jie Tang, Guo-Qi Gao, Ba-Yi Li, Bin Zhao, Feng-Xian Zheng, Cui-Hong Dai, Meng Guo, Jun Zhao, Ying-Ying Su, Jun-Zhi Wang, Feng-Cai Zhu, Shao-Wei Li, Hui-Rong Pan, Yi-Min Li, Jun Zhang, Ningshao Xia
DOI https://doi.org/10.1093/jnci/djz074

Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial

DATE July 31, 2015
Title Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial
Journal Vaccine, 2015; 33(32):3940–3946
Authors Ting Wu, Yue-Mei Hu, Juan Li, Kai Chu, Shou-Jie Huang, Hui Zhao, Zhong-Ze Wang, Chang-Lin Yang, Han-Min Jiang, Yi-Jun Wang, Zhi-Jie Lin, Hui-Rong Pan, Wei Sheng, Fei-Xue Wei, Shao-Wei Li, Ying Wang, Feng-Cai Zhu, Chang-Gui Li, Jun Zhang, Ningshao Xia
DOI https://doi.org/10.1016/j.vaccine.2015.06.052

Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: An open-label phase I clinical trial

DATE October 25, 2013
Title Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: An open-label phase I clinical trial
Journal Human Vaccines & Immunotherapeutics, 2014; 10(2):469–475
Authors Yue-Mei Hu, Shou-Jie Huang, Kai Chu, Ting Wu, Zhong-Ze Wang, Chang-Lin Yang, Jia-Ping Cai, Han-Min Jiang, Yi-Jun Wang, Meng Guo, Xiao-Hui Liu, Hong-Jiang Huang, Feng-Cai Zhu, Jun Zhang, Ningshao Xia
DOI https://doi.org/10.4161/hv.26846

Hecolin

Immunogenicity and safety of co-administered Escherichia coli-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine

DATE May 29, 2026
Title Immunogenicity and safety of co-administered Escherichia coli-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine
Journal Frontiers in Immunology, 2026; 17:1837539
Authors Rui Yan, Mengting Cen, Yang Zhou, Liyang Ma, Xiaofei Zhou, Hanqing He, Xiaohua Qi, Xuewen Tang, Hui Liang, Yaping Chen, Jiaxing Qi, Shigui Yang
DOI https://doi.org/10.3389/fimmu.2026.1837539

Long-term protection from naturally acquired immunity against hepatitis E virus reinfection

DATE December 17, 2025
Title Long-term protection from naturally acquired immunity against hepatitis E virus reinfection
Journal Nature Communications, 2025; 16: 11187
Authors Xiaohui Liu, Xia Zang, Kongxin Zhu, Xingcheng Huang, Xiaowen Hu, Zhaofeng Bi, Qi Chen, Hanmin Jiang, Yijun Wang, Changlin Yang, Donglin Liu, Wenhua Zhu, Zizheng Zheng, Yingying Su, Ting Wu, Shoujie Huang, Chunlan Zhuang, Jun Zhang, and Ningshao Xia
DOI https://doi.org/10.1038/s41467-025-66188-8

 

Safety and immunogenicity of thiomersal-free recombinant hepatitis E vaccine: A randomized, double-blind, active-controlled study

DATE July 20, 2025
Title Safety and immunogenicity of thiomersal-free recombinant hepatitis E vaccine: A randomized, double-blind, active-controlled study
Journal Vaccine, 2025; 62: 127510
Authors Junrong Li, Xiujuan Wang, Dengxiang Zhang, Fangqin Xie, Sumei Zhong, Xiaoshan Yu, Shasha Chen, Qinbiao Huang, Rui Wang, Qiufen Zhang, and Dongjuan Zhang
DOI https://doi.org/10.1016/j.vaccine.2025.127510

High confidence and demand for hepatitis E vaccine during an outbreak in Bentiu, South Sudan: A qualitative study

DATE March 6, 2025
Title High confidence and demand for hepatitis E vaccine during an outbreak in Bentiu, South Sudan: A qualitative study
Journal PLOS Global Public Health, 2025; 5(3): e0003482
Authors Aybüke Koyuncu, Kinya Vincent Asilaza, John Rumunu, Joseph Wamala, Priscillah Gitahi, Zelie Antier, Jetske Duncker, Patrick Nkemenang, Primitive Gakima, Melat Haile, Etienne Gignoux, Manuel Albela, Frederick Beden Loro, Duol Biem, Monica Rull, Andrew S. Azman, Iza Ciglenecki, and Robin Nesbitt
DOI https://doi.org/10.1371/journal.pgph.0003482

Safety and immunogenicity of hepatitis E vaccine in compensated liver cirrhosis with chronic hepatitis B

DATE February 22, 2025
Title Safety and immunogenicity of hepatitis E vaccine in compensated liver cirrhosis with chronic hepatitis B
Journal Clinical Microbiology and Infection, Corrected proof
Authors Xuejiao Liao, Dapeng Li, Yingying Su, Xinwu Wang, Shuting Wu, Yanling Chen, Zhiyu Li, Qiyuan Tang, Zhenghua Ma, Xiaobin Wan, Jingke Dong, Liping Zhang, Changxiang Lai, Haiyan Wang, Qing He, Jun Zhang, Fang Wang, and Zheng Zhang
DOI https://doi.org/10.1016/j.cmi.2025.02.027

Effectiveness of a hepatitis E vaccine against medically-attended symptomatic infection in HBsAg-positive adults from a test-negative design study

DATE February 19, 2025
Title Effectiveness of a hepatitis E vaccine against medically-attended symptomatic infection in HBsAg-positive adults from a test-negative design study
Journal Nature Communications, 2025; 16: 1699
Authors Chunlan Zhuang, Xiaohui Liu, Xingcheng Huang, Jiaoxi Lu, Kongxin Zhu, Mengjun Liao, Lu Chen, Hanmin Jiang, Xia Zang, Yijun Wang, Changlin Yang, Donglin Liu, Zizheng Zheng, Xuefeng Zhang, Shoujie Huang, Yue Huang, Yingying Su, Ting Wu, Jun Zhang, and Ningshao Xia
DOI https://doi.org/10.1038/s41467-025-57021-3

Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China

DATE January 10, 2025
Title Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China
Journal Human Vaccines & Immunotherapeutics, 2025; 21(1): 2448882
Authors Li Zhang, Qiufen Zhang, Jiaye Liu, Wenlong Wu, Zechun Jiang, Bingyu Yan, Qingfan Cao, Haidong Liu, Huirong Pan, Jingjing Lv, Yi Feng, Fujie Xu, Shoujie Huang, and Aiqiang Xu
DOI https://doi.org/10.1080/21645515.2024.2448882

The effectiveness of two doses of recombinant hepatitis E vaccine in response to an outbreak in Bentiu, South Sudan: a case–control and bias indicator study

DATE January 8, 2025
Title The effectiveness of two doses of recombinant hepatitis E vaccine in response to an outbreak in Bentiu, South Sudan: a case–control and bias indicator study
Journal The Lancet Infectious Diseases, 2025; 25: 537–547
Authors Robin C Nesbitt, Vincent Kinya Asilaza, Catia Alvarez, Priscillah Gitahi, Patrick Nkemenang, Jetske Duncker, Melat Haile, Primitive Gakima, Joseph F Wamala, Fredrick Beden Loro, Aybüke Koyuncu, Duol Biem, Manuel Albela, Monica Rull, Etienne Gignoux, John Rumunu, Isabella Eckerle, Iza Ciglenecki, and Andrew S Azman
DOI https://doi.org/10.1016/S1473-3099(24)00657-1

Immunogenicity, Efficacy, and Effectiveness of Two-Dose and Shorter Schedules of Hepatitis E Vaccine: A Systematic Review

DATE December 31, 2024
Title Immunogenicity, Efficacy, and Effectiveness of Two-Dose and Shorter Schedules of Hepatitis E Vaccine: A Systematic Review
Journal Vaccines, 2025; 13: 28
Authors Bilal Azam, Melanie Marti, Amit Goel, and Rakesh Aggarwal
DOI https://doi.org/10.3390/vaccines13010028

Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus

DATE December 19, 2024
Title Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus
Journal npj Vaccines, 2024; 9: 245
Authors Kongxin Zhu, Mengjun Liao, Lu Chen, Jiaoxi Lu, Xingcheng Huang, Chunlan Zhuang, Yingying Su, Shoujie Huang, Ting Wu, Jun Zhang, and Ningshao Xia
DOI https://doi.org/10.1038/s41541-024-01041-5

Safety of hepatitis E vaccine in pregnancy: an emulated target trial following a mass reactive vaccination campaign in Bentiu internally displaced persons camp, South Sudan

DATE November, 2024
Title Safety of hepatitis E vaccine in pregnancy: an emulated target trial following a mass reactive vaccination campaign in Bentiu internally displaced persons camp, South Sudan
Journal The Lancet Global Health, 2024; 12: e1881–e1890
Authors Robin C Nesbitt, Andrew S Azman, Vincent Kinya Asilaza, Jessie K Edwards, Priscillah Gitahi, Patrick Nkemenang, Jetske Duncker, Melat Haile, Primitive Gakima, Joseph F Wamala, Fredrick Beden Loro, Duol Biem, Nelly Staderini, Manuel Albela, Monica Rull, John Rumunu, Iza Ciglenecki, and Etienne Gignoux
DOI https://doi.org/10.1016/S2214-109X(24)00321-8

Safety and effectiveness of a recombinant hepatitis E vaccine in women of childbearing age in rural Bangladesh: a phase 4, double-blind, cluster-randomised, controlled trial

DATE August, 2024
Title Safety and effectiveness of a recombinant hepatitis E vaccine in women of childbearing age in rural Bangladesh: a phase 4, double-blind, cluster-randomised, controlled trial
Journal The Lancet Global Health, 2024; 12: e1288–e1299
Authors Khalequ Zaman, Cathinka Halle Julin, Asma Binte Aziz, Kathrine Stene-Johansen, Md Yunus, Firdausi Qadri, Emily S Gurley, Synne Sandbu, Joakim Øverbø, Jennifer L Dembinski, Ida Laake, Taufiqur R Bhuiyan, Mustafizur Rahman, Warda Haque, Mahbuba Khanam, John D Clemens, and Susanne Dudman
DOI https://doi.org/10.1016/S2214-109X(24)00192-X

Receipt of hepatitis E vaccine and fetal loss in rural Bangladesh: further analysis of a double-blind, cluster-randomised, controlled trial

DATE August, 2024
Title Receipt of hepatitis E vaccine and fetal loss in rural Bangladesh: further analysis of a double-blind, cluster-randomised, controlled trial
Journal The Lancet Global Health, 2024; 12: e1300–e1311
Authors Asma Binte Aziz, Susanne Dudman, Cathinka Halle Julin, Faisal Ahmmed, Kathrine Stene-Johansen, Synne Sandbu, Joakim Øverbø, Jennifer L Dembinski, Torbjørn Wisløff, Sohel Rana, Ahsan-ul Habib Basunia, Warda Haque, Firdausi Qadri, Khalequ Zaman, and John D Clemens
DOI https://doi.org/10.1016/S2214-109X(24)00193-1

A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults

DATE March 27, 2024
Title A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
Journal The Journal of Infectious Diseases, 2024; 230: 1093–1101
Authors Carol M. Kao, Christina A. Rostad, Lauren E. Nolan, Etza Peters, Jennifer Kleinhenz, Jacob D. Sherman, Ashley Tippett, J. Wai Kuo Shih, Inci Yildirim, Vivien Agbakoba, Tatiana Beresnev, Cassandra Ballou, Satoshi Kamidani, Vinit Karmali, Muktha Natrajan, Erin M. Scherer, Nadine Rouphael, and Evan J. Anderson
DOI https://doi.org/10.1093/infdis/jiae148

Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

DATE February 19, 2024
Title Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
Journal The Lancet, 2024; published online
Authors Shoujie Huang, Xuefeng Zhang, Yingying Su, Chunlan Zhuang, Zimin Tang, Xingcheng Huang, Qi Chen, Kongxin Zhu, Xiaowen Hu, Ying Dong, Xiaohui Liu, Hanmin Jiang, Xia Zang, Zhongze Wang, Changlin Yang, Donglin Liu, Yijun Wang, Quan Tang, Wendong Shen, Huanhuan Cao, Huirong Pan, Shengxiang Ge, Yue Huang, Ting Wu, Zizheng Zheng, Fengcai Zhu, Jun Zhang, and Ningshao Xia
DOI https://doi.org/10.1016/S0140-6736(23)02234-1

Vaccination coverage and adverse events following a reactive vaccination campaign against hepatitis E in Bentiu displaced persons camp, South Sudan

DATE January 22, 2024
Title Vaccination coverage and adverse events following a reactive vaccination campaign against hepatitis E in Bentiu displaced persons camp, South Sudan
Journal PLOS Neglected Tropical Diseases, 2024; 18(1): e0011661
Authors Robin C. Nesbitt, Vincent Kinya Asilaza, Etienne Gignoux, Aybüke Koyuncu, Priscillah Gitahi, Patrick Nkemenang, Jetske Duncker, Zelie Antier, Melat Haile, Primitive Gakima, Joseph F. Wamala, Fredrick Beden Loro, Duol Biem, Monica Rull, Andrew S. Azman, John Rumunu, and Iza Ciglenecki
DOI https://doi.org/10.1371/journal.pntd.0011661

Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial

DATE March 15, 2023
Title Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial
Journal Emerging Microbes & Infections, 2023; 12: 2185456
Authors Guohua Zhong, Chunlan Zhuang, Xiaowen Hu, Qi Chen, Zhaofeng Bi, Xinhua Jia, Siying Peng, Yufei Li, Yue Huang, Qiufen Zhang, Ying Hong, Youlin Qiao, Yingying Su, Huirong Pan, Ting Wu, Lihui Wei, Shoujie Huang, Jun Zhang, and Ningshao Xia
DOI https://doi.org/10.1080/22221751.2023.2185456

Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial

DATE December 28, 2022
Title Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial
Journal Vaccine, Corrected proof
Authors Joakim Øverbø, Asma Aziz, K Zaman, John Clemens, Cathinka Halle Julin, Firdausi Qadri, Kathrine Stene-Johansen, Rajib Biswas, Shaumik Islam, Taufiqur Rahman Bhuiyan, Warda Haque, Synne Sandbu, Manzoor E Elahee, Mohammad Ali, Jennifer L Dembinski, and Susanne Dudman
DOI https://doi.org/10.1016/j.vaccine.2022.12.064

Consistency of safety and immunogenicity of three consecutive batches of hepatitis E vaccine in healthy people over 18 years of age

DATE December, 2022
Title Consistency of safety and immunogenicity of three consecutive batches of hepatitis E vaccine in healthy people over 18 years of age
Journal Chinese Journal of Biologicals, 2022; 35(12): 1477–1481
Authors Yu Xiaoshan, Li Xiaohua, Feng Hao, Wei Mingwei, Wang Wenjuan, Liu Donglin, Yang Changlin, Jiang Hanmin, Zhang Qiufen, and Hu Yuemei
DOI https://doi.org/10.13200/j.cnki.cjb.003763

The first reactive vaccination campaign against hepatitis E

DATE August, 2022
Title The first reactive vaccination campaign against hepatitis E
Journal The Lancet Infectious Diseases, 2022; 22: 1110–1111
Authors Iza Ciglenecki, John Rumunu, Joseph F Wamala, Patrick Nkemenang, Jetske Duncker, Robin Nesbitt, Etienne Gignoux, Trish Newport, Melat Heile, Christine Jamet, Monica Rull, and Andrew S Azman
DOI https://doi.org/10.1016/S1473-3099(22)00421-2

Evaluation of safety and immunogenicity of hepatitis E vaccine in maintenance hemodialysis patients

DATE April 6, 2022
Title Evaluation of safety and immunogenicity of hepatitis E vaccine in maintenance hemodialysis patients
Journal Chinese Journal of Preventive Medicine, 2022; 56(4): 464–467
Authors Wang Xuelian, Li Yanting, Ma Xinjing, Ling Yisheng, Wu Ting, and Niu Jianjun
DOI https://doi.org/10.3760/cma.j.cn112150-20220223-00168

HEV study protocol: design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh

DATE January 19, 2020
Title HEV study protocol: design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh
Journal BMJ Open, 2020; 10: e033702
Authors K Zaman, Susanne Dudman, Kathrine Stene-Johansen, Firdausi Qadri, Md Yunus, Synne Sandbu, Emily S Gurley, Joakim Øverbø, Cathinka Halle Julin, Jennifer Lynn Dembinski, Quamrun Nahar, Anisur Rahman, Taufiqur R Bhuiyan, Mustafizur Rahman, Warda Haque, Jahangir Khan, Asma Aziz, Mahbuba Khanam, Peter Kim Streatfield, and John D Clemens
DOI https://doi.org/10.1136/bmjopen-2019-033702

Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years

DATE June 28, 2019
Title Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years
Journal Vaccine, 2019; 37: 4581–4586
Authors Xu-ya Yu, Zhi-ping Chen, Shen-yu Wang, Hui-rong Pan, Zhi-fang Wang, Qiu-fen Zhang, Ling-zhi Shen, Xiao-ping Zheng, Chuan-fu Yan, Mei Lu, Bo Chen, Ya Zheng, Jun Zhang, Hua-kun Lv, and Shou-jie Huang
DOI https://doi.org/10.1016/j.vaccine.2019.04.006

Study on the safety and immunogenicity of simultaneous vaccination on both hepatitis E and hepatitis B vaccines

DATE April 10, 2019
Title Study on the safety and immunogenicity of simultaneous vaccination on both hepatitis E and hepatitis B vaccines
Journal Chinese Journal of Epidemiology, 2019; 40(4): 451–455
Authors Ma Jianxin, Liu Yuqiang, Li Qian, Ge Shen, and Zhang Zheng
DOI https://doi.org/10.3760/cma.j.issn.0254-6450.2019.04.015

Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial

DATE January 31, 2019
Title Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial
Journal Clinical Microbiology and Infection, 2019; 25: 1133–1139
Authors Z. Chen, S. Lin, J. Duan, Y. Luo, S. Wang, Z. Gan, H. Yi, T. Wu, S. Huang, Q. Zhang, and H. Lv
DOI https://doi.org/10.1016/j.cmi.2019.01.015

Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination

DATE November 9, 2016
Title Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination
Journal Clinical Microbiology and Infection, 2017; 23: 336.e1–336.e4
Authors Y.-Y. Su, S.-J. Huang, M. Guo, J. Zhao, H. Yu, W.-G. He, H.-M. Jiang, Y.-J. Wang, X.-F. Zhang, J.-P. Cai, C.-L. Yang, Z.-Z. Wang, F.-C. Zhu, T. Wu, J. Zhang, and N.-S. Xia
DOI https://doi.org/10.1016/j.cmi.2016.10.029

Modeling the long-term antibody response of a hepatitis E vaccine

DATE June 8, 2015
Title Modeling the long-term antibody response of a hepatitis E vaccine
Journal Vaccine, 2015; Article in Press
Authors Shu Chen, Zi Zhou, Fei-Xue Wei, Shou-Jie Huang, Zhong Tan, Ya Fang, Feng-Cai Zhu, Ting Wu, Jun Zhang, and Ning-Shao Xia
DOI https://doi.org/10.1016/j.vaccine.2015.06.050

Long-Term Efficacy of a Hepatitis E Vaccine

DATE March 5, 2015
Title Long-Term Efficacy of a Hepatitis E Vaccine
Journal The New England Journal of Medicine, 2015; 372: 914–922
Authors Jun Zhang, Xue-Feng Zhang, Shou-Jie Huang, Ting Wu, Yue-Mei Hu, Zhong-Ze Wang, Hua Wang, Han-Min Jiang, Yi-Jun Wang, Qiang Yan, Meng Guo, Xiao-Hui Liu, Jing-Xin Li, Chang-Lin Yang, Quan Tang, Ren-Jie Jiang, Hui-Rong Pan, Yi-Min Li, J. Wai-Kuo Shih, Mun-Hon Ng, Feng-Cai Zhu, and Ning-Shao Xia
DOI https://doi.org/10.1056/NEJMoa1406011

Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity

DATE November 18, 2013
Title Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity
Journal Clinical Microbiology and Infection, 2014; 20: O397–O405
Authors J. Zhang, X.-F. Zhang, C. Zhou, Z.-Z. Wang, S.-J. Huang, X. Yao, Z.-L. Liang, T. Wu, J.-X. Li, Q. Yan, C.-L. Yang, H.-M. Jiang, H.-J. Huang, Y.-L. Xian, J. W.-K. Shih, M.-H. Ng, Y.-M. Li, J.-Z. Wang, F.-C. Zhu, and N.-S. Xia
DOI https://doi.org/10.1111/1469-0691.12419

Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults

DATE July 25, 2013
Title Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults
Journal Human Vaccines & Immunotherapeutics, 2013; 9(11): 2474–2479
Authors Ting Wu, Shou-Jie Huang, Feng-Cai Zhu, Xue-Feng Zhang, Xing Ai, Qiang Yan, Zhong-Ze Wang, Chang-Lin Yang, Han-Min Jiang, Xiao-Hui Liu, Meng Guo, Hai-Lian Du, Mun-Hon Ng, Jun Zhang, and Ning-Shao Xia
DOI https://doi.org/10.4161/hv.25814

Safety of the Hepatitis E Vaccine for Pregnant Women: A Preliminary Analysis

DATE June, 2012
Title Safety of the Hepatitis E Vaccine for Pregnant Women: A Preliminary Analysis
Journal Hepatology, 2012; 56(6): 2038
Authors Ting Wu, Feng-Cai Zhu, Shou-Jie Huang, Xue-Feng Zhang, Zhong-Ze Wang, Jun Zhang, and Ning-Shao Xia
DOI https://doi.org/10.1002/hep.25522

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial

DATE August 23, 2010
Title Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial
Journal The Lancet, 2010; 376: 895–902
Authors Feng-Cai Zhu, Jun Zhang, Xue-Feng Zhang, Cheng Zhou, Zhong-Ze Wang, Shou-Jie Huang, Hua Wang, Chang-Lin Yang, Han-Min Jiang, Jia-Ping Cai, Yi-Jun Wang, Xing Ai, Yue-Mei Hu, Quan Tang, Xin Yao, Qiang Yan, Yang-Ling Xian, Ting Wu, Yi-Min Li, Ji Miao, Mun-Hon Ng, James Wai-Kuo Shih, and Ning-Shao Xia
DOI https://doi.org/10.1016/S0140-6736(10)61030-6

Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine

DATE January 23, 2009
Title Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine
Journal Vaccine, 2009; 27: 1869–1874
Authors Jun Zhang, Chong-bo Liu, Rong-cheng Li, Yi-min Li, Ying-jie Zheng, Yan-ping Li, Dong Luo, Bai-bin Pan, Yi Nong, Sheng-Xiang Ge, Jun-hui Xiong, James Wai-kuo Shih, Mun-Hon Ng, and Ning-shao Xia
DOI https://doi.org/10.1016/j.vaccine.2008.12.061